RUVBL1 and cancer: Assimon et al. identified an allosteric inhibitor of the ATPase domain of RUVBL1/2, named CB-6644, which can suppress the progression of many cancers.530 Besides, Nano et al. indicated that sorafenib inhibited the ATPase activity of RUVBL1/2 complex by directly interacting with RUVBL2.531